MedTrace Logo

PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia

NCT05919199 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-06-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the predictive value of 18F-FDG PET probe signal in de novo diagnosed or refractory/relapsed patients with acute myeloid leukemia. It is hypothesized that the intensity of 18F-FDG signal, an indicator of glucose uptake capacity, in various cell subsets of bone marrow will improve the predictive effect of clinical standard prognostic work-up.

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • First Affiliated Hospital of Jinan University

    lead OTHER

Principal Investigators

  • Hui Zeng · First Affiliated Hopital of Jinan University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05919199 on ClinicalTrials.gov